Inducible Co-stimulator Gene With Systemic Lupus Erythematosus
ConditionSystemic Lupus Erthematosus
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-65
SponsorSouth Valley University
About this trial
The aim of this study is to investigate the association between ICOS gene polymorphism and susceptibility to systemic lupus erythematosus (SLE), as well as its impact on disease severity.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Patients diagnosed with SLE based on 2019 EULAR/ACR Male or female. willing to provide written informed consent for participation and genetic testing
Disqualifiers
Other autoimmune diseases or chronic inflammatory disorders. Malignancy. Pregnancy or breastfeeding. Inability to provide informed consent.
Trial population
group A: systemic lupus erythrematosus patients about 20 patients diagnosed with SLE based on 2019 EULAR/ACR. group B:healthy controls 10 with no personal or family history of autoimmune diseases or chronic inflammatory disorders
Trial design
Design model
Case-control
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
30 Participants
are grouped into 2 trial groupsGroup A: group A: systemic lupus erythrematosus
Group B: group B:healthy controls
Trial outcomes
Primary outcomes
1
ICOS gene polymorphism and SLE
association between ICOS gene polymorphism and SLE susceptibility
Time frame
6 monthSecondary outcomes
1
systemic lupus erythematosus (SLE) Assessment
the impact of the ICOS gene polymorphism on disease severity and activity using the Systemic Lupus Erythematosus Disease Activity Index Index (SLEDAI).
Time frame
6 monthSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: